Imperial College London
Alternate

Jiri Pavlu

Faculty of Medicine, Department of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Loke:2022:10.1111/bjh.17823,
author = {Loke, J and Metzner, M and Boucher, R and Jackson, A and Hopkins, L and Pavlu, J and Tholouli, E and Drummond, M and Peniket, A and Bishop, R and Fox, S and Vyas, P and Craddock, C},
doi = {10.1111/bjh.17823},
journal = {BRITISH JOURNAL OF HAEMATOLOGY},
pages = {368--373},
title = {Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy},
url = {http://dx.doi.org/10.1111/bjh.17823},
volume = {196},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Loke,J
AU  - Metzner,M
AU  - Boucher,R
AU  - Jackson,A
AU  - Hopkins,L
AU  - Pavlu,J
AU  - Tholouli,E
AU  - Drummond,M
AU  - Peniket,A
AU  - Bishop,R
AU  - Fox,S
AU  - Vyas,P
AU  - Craddock,C
DO  - 10.1111/bjh.17823
EP  - 373
PY  - 2022///
SN  - 0007-1048
SP  - 368
TI  - Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
T2  - BRITISH JOURNAL OF HAEMATOLOGY
UR  - http://dx.doi.org/10.1111/bjh.17823
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000692933100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 196
ER  -
Download